RPSAP52

Across TCGA pan-cancer cohorts, RPSAP52 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPSAP52 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RPSAP52 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPSAP52 expression acts as an unfavorable survival marker.

BLCA, LUSC, and LGG are the cancer types where RPSAP52 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.132	0.720	<.001	42	view →
LUSC	OS	Median	All	0.505	0.762	<.001	20	view →
LGG	OS	Median	All	0.195	0.889	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	III,IV	0.520	0.817	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPSAP52–BLCA (OS)

Open the BLCA breakdown →